Entresto Cleared In Europe As Reimbursement Delay Stunts US Uptake
This article was originally published in Scrip
Novartis AG's Entresto, which has had sluggish US sales since launch earlier this year, has been granted marketing authorization in the EU for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.